Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677613 | 0.89 | ACHE (0.66) | ACHECYP2A6MAOAMAOBCES1 | |
| SCHEMBL10000875 | 0.89 | ACHE (0.66) | ACHECYP2A6MAOAMAOBCES1 | |
| SCHEMBL12676173 | 0.89 | ACHE (0.66) | ACHECYP2A6MAOAMAOBCES1 | |
| SCHEMBL25001243 | 0.89 | ACHE (0.66) | ACHECYP2A6MAOAMAOBCES1 | |
| SCHEMBL11090923 | 0.81 | CYP2A6 (0.53) | ACHECYP2A6MAOAMAOBCES1 | |
| SCHEMBL15291325 | 0.79 | CYP2A6 (0.52) | ACHECYP2A6MAOAMAOBCES1 | |
| SCHEMBL8636464 | 0.78 | PTPRC (0.46) | ACHECYP2A6MAOAMAOB | |
| SCHEMBL12500873 | 0.78 | CYP2A6 (0.50) | ACHECYP2A6MAOAMAOBCES1 | |
| SCHEMBL2592601 | 0.78 | MAOA (0.50) | ACHECYP2A6MAOAMAOBCES1 | |
| SCHEMBL15700140 | 0.77 | ACHE (0.56) | ACHECYP2A6MAOAMAOBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3902878-B1 | PHOTOINITIATORS | IGM RESINS ITALIA SRL (IT) | 2026-05-06 | — | — | EP | disclosed |
| US-11834532-B2 | Photoinitiators | IGH RESINS ITALIA S.R.L. (IT) | 2023-12-05 | — | — | US | disclosed |
| US-20220098333-A1 | PHOTOINITIATORS | IGM RESINS ITALIA S.R.L. (IT) | 2022-03-31 | — | — | US | disclosed |
| EP-3902878-A1 | PHOTOINITIATORS | IGM Resins Italia S.r.l. (IT) | 2021-11-03 | — | — | EP | disclosed |
| WO-2020136522-A1 | PHOTOINITIATORS | IGM RESINS ITALIA S.R.L. (IT) | 2020-07-02 | — | — | WO | disclosed |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2018-01-18 | — | — | US | disclosed |
| US-20160271108-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | AGENEBIO, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110053981-A1 | Methods and Compositions Using Cholinesterase Inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20070129402-A1 | Donepezil; pharmacokinetics; single-dose administration of the formulation to a patient provides a blood plasma level profile with a dosage-corrected Cmax | EISAI RESEARCH INSTITUTE (US) | 2007-06-07 | — | — | US | disclosed |
| EP-1764101-A1 | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments | Eisai R&D Management Co., Ltd. (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-20070021397-A1 | Neurocyte protective agent | EISAI CO., LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | EISAI CO., LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | EISAI CO., LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021397-A1 | Neurocyte protective agent | CHAT, GAP43, NES | ACHE 6/4885CYP2A6 3811/4885MAOA 160/4885 |
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | ACHE 2269/4885CYP2A6 1012/4885MAOA 3227/4885 |
| US-20160271108-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, BACE1, GRIN2A | ACHE 4/4885CYP2A6 2312/4885MAOA 123/4885 |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | ACHE, BPHL, GLA | ACHE 1/4885CYP2A6 2258/4885MAOA 41/4885 |
| US-20070129402-A1 | Donepezil; pharmacokinetics; single-dose administration of the formulation to a patient provides a blood plasma level profile with a dosage-corrected Cmax | CYP3A5, SLC6A2, SLC6A4 | ACHE 4/4885CYP2A6 36/4885MAOA 167/4885 |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | ACHE 3/4885CYP2A6 2119/4885MAOA 374/4885 |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | ACHE, CHAT, BCHE | ACHE 1/4885CYP2A6 2896/4885MAOA 50/4885 |
| US-20110053981-A1 | Methods and Compositions Using Cholinesterase Inhibitors | PSEN1, BACE1, PSENEN | ACHE 26/4885CYP2A6 4053/4885MAOA 1099/4885 |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | ACHE 3/4885CYP2A6 2119/4885MAOA 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.